Basilea reports pooled efficacy data for derazantinib in iCCA patients with FGFR2 gene mutations and amplifications presented at ESMO MAP Virtual Congress 2020

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Stacey Gandler
Brand Nourishment

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition